Cardiovascular Indicators and Mitral Valve Disease in Dogs with Spontaneous Hypercortisolism - Prospective Evaluation
DOI:
https://doi.org/10.22456/1679-9216.129305Abstract
Background: Canine hypercortisolism (HC) is the most prevalent endocrinopathy in dogs in southern Brazil. The prognosis depends on several factors including the general health status, owners´ commitment, and the development of disease complications and comorbidities occurrence, such as cardiovascular complications including mitral valve disease (MVD), systemic arterial hypertension, and left ventricular hypertrophy. The main objective of the present study was to assess cardiovascular parameters in canine HC, based on investigating survival-related variables. The study also aimed to evaluate the influence of concurrent preclinical (MVD) on dogs` survival and the impact of HC on MVD progression.
Materials, Methods & Results: A total of 25 dogs with spontaneous HC were enrolled and divided into 2 subgroups accordingly to their echocardiographic findings: group HC (normal echocardiography at first evaluation, n = 16); and group HC + MVD (concurrent presence of stages B1 and B2 MVD diagnosed at the first evaluation, n = 9). The patients were evaluated at diagnosis (T0); 6 months after treatment begging (T1); and after 12 months of treatment (T2). The owners were further contacted by phone or e-mail for 1 more year after T2 regarding survival information. A control group (CG, n = 20) was also evaluated at T0 and T1. At each evaluation, dogs were submitted to a complete clinical evaluation and physical exam, associated with a minimum database (CBC, serum biochemistry, and urine analysis) and cardiovascular evaluation composed of systolic blood pressure determination, electrocardiogram (ECG), and echodopplercardiography. In the HC group, 11/16 dogs underwent the evaluation at T2, while 4/9 dogs from the HC + MVD group and 17/20 dogs from the CG underwent the evaluation at T2. Five dogs (31.25%) from the HC group and 4 dogs (44.44%) from the HC + MVD group died before the end of the follow-up period. In the control group, only 1 dog (5.26%) died before the end of the study. Despite the higher mortality in the HC + MVD group during the follow-up period, there was no significant difference (P = 0.632) in survival when compared with the HC group. The MVD of 4 dogs included in the HC + MVD group was classified as stage B1, while the other 5 dogs were classified as stage B2. Only 1 dog from the CG developed stage B1 MVD in the period studied; however, progression of the MVD stage was documented in 1/4 of dogs in the HC + MVD group and MVD development was documented in 3/11 of dogs from the HC group from T0 to T2. The odds ratio (OR) and respective 95% confidence interval (95%CI) for HC as a risk factor for MVD progression were 4.267 (0.4268 - 42.65; P = 0.342). Exercise intolerance (12/16 dogs) and dyspnea (6/16 dogs) were the cardiorespiratory clinical signs with the highest incidence in the HC group at T0. When compared to the control group, both exercise intolerance (P < 0.001) and dyspnea (P = 0.03) occurrence were significantly higher in the HC group. The age (P = 0.001) and the occurrence of dyspnea (P = 0.036) at diagnosis were significantly higher in dogs with HC that died during the follow-up than those that remained alive. Regarding the occurrence of cardiac arrhythmias verified by ECG, no statistically significant differences were observed among groups.
Discussion: The study suggests that systemic hypertension and altered echocardiographic measurements did not interfere with dogs´ survival; however, dyspnea was associated with a worse prognosis. Finally, it is possible to conclude that mitral valve degeneration is a common comorbidity in dogs with HC, however, it was not evidenced their interference in the survival of dogs with this endocrine disease or even a role of the HC in the progression of the MVD.
Keywords: Cushing's syndrome, hyperadrenocorticism, dyspnea, echocardiography, prognosis.
Downloads
References
Acierno M.J., Brown S., Coleman A.E., Jepson R.E., Papich M., Stepien R.L. & Syme H.M. 2018. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. Consensus Statements of the American College of Veterinary Internal Medicine. Journal of Veterinary Internal Medicine. 32(6): 1803-1822. DOI: 10.1111/jvim.15331 DOI: https://doi.org/10.1111/jvim.15331
Arenas C., Melián C. & Pérez-Alenza M.D. 2014. Long-term survival of dogs with adrenal dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment. Journal of Veterinary Internal Medicine. 28(2): 473-480. DOI: 10.1111/jvim.12303 DOI: https://doi.org/10.1111/jvim.12303
Avenatti E., Rebellato A., Iannaccone A., Battocchio M., Dassie F., Veglio F., Milan A. & Fallo F. 2017. Left ventricular geometry and 24-h blood pressure profile in Cushing's syndrome. Endocrine. 55(2): 547-554. DOI: 10.1007/s12020-016-0986-6 DOI: https://doi.org/10.1007/s12020-016-0986-6
Bannas P., Bell L.C., Johnson K.M., Schiebler M.L., François C.J., Motosugi U., Consigny D., Reeder S.B. & Nagle S.K. 2016. Pulmonary Embolism Detection with Three-dimensional Ultrashort Echo Time MR Imaging: Experimental Study in Canines. Radiology. 278(2): 413-421. DOI: 10.1148/radiol.2015150606 DOI: https://doi.org/10.1148/radiol.2015150606
Barker E.N., Campbell S., Tebb A.J., Neiger R., Herrtage M.E., Reid S.W. & Ramsey I.K. 2005. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. Journal of Veterinary Internal Medicine. 19(6): 810-815. DOI: 10.1111/j.1939-1676.2005.tb02769.x DOI: https://doi.org/10.1111/j.1939-1676.2005.tb02769.x
Behrend E.N., Kooistra H.S., Nelson R., Reusch C.E. & Scott-Moncrieff J.C. 2013. Diagnosis of spontaneous canine hyperadrenocorticism: 2012 Consensus Statements of the American College of Veterinary Internal Medicine (small animal). Journal of Veterinary Internal Medicine. 27(6): 1292-304. DOI: 10.1111/jvim.12192 DOI: https://doi.org/10.1111/jvim.12192
Berry C.R., Hawkins E.C., Hurley K.J. & Monce K. 2000. Frequency of pulmonary mineralization and hypoxemia in 21 dogs with pituitary-dependent hyperadrenocorticism. Journal of Veterinary Internal Medicine. 14(2): 151-156. DOI: 10.1892/0891-6640(2000)014<0151:fopmah>2.3.co;2 DOI: https://doi.org/10.1111/j.1939-1676.2000.tb02229.x
Boon J.A. 2011. Veterinary Echocardiography. 2.Ed. Oxford: Wiley-Blackwell, pp.678-703.
Brown S., Atkins C., Bagley R., Carr A., Cowgill L., Davidson M., Egner B., Elliott J., Henik R., Labato M., Littman M., Polzin D., Ross L., Snyder P. & Stepien R. 2007. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. Journal of Veterinary Internal Medicine. 21(3): 542-558. DOI: 10.1892/0891-6640(2007)21[542:gftiea]2.0.co;2 DOI: https://doi.org/10.1111/j.1939-1676.2007.tb03005.x
Carotenuto G., Malerba E., Dolfini C., Brugnoli F., Giannuzzi P., Semprini G., Tosolini P. & Fracassi F. 2019. Cushing's syndrome-an epidemiological study based on a canine population of 21,281 dogs. Open Veterinary Journal. 9(1): 27-32. DOI: 10.4314/ovj.v9i1.5 DOI: https://doi.org/10.4314/ovj.v9i1.5
Chen H., Lien Y. & Huang H. 2014. Assessment of left ventricular function by two-dimensional speckle-tracking echocardiography in small breed dogs with hyperadrenocorticism. Acta Veterinaria Scandinavica. 56: 1-10. DOI: 10.1186/s13028-014-0088-5 DOI: https://doi.org/10.1186/s13028-014-0088-5
Chetboul V. & Tissier R. 2012. Echocardiographic assessment of canine degenerative mitral valve disease. Journal of Veterinary Cardiology. 14(1): 127-148. DOI: 10.1016/j.jvc.2011.11.005 DOI: https://doi.org/10.1016/j.jvc.2011.11.005
Faggiano A., Pivonello R., Spiezia S., De Martino M.C., Filippella M., Di Somma C., Lombardi G. & Colao A. 2003. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. The Journal of Clinical Endocrinology and Metabolism. 88(6): 2527-2533. DOI: 10.1210/jc.2002-021558 DOI: https://doi.org/10.1210/jc.2002-021558
Fallo F., Maffei P., Dalla Pozza A., Carli M., Della Mea P., Lupia M., Rabbia F. & Sonino N. 2009. Cardiovascular autonomic function in Cushing's syndrome. Journal of Endocrinological Investigation. 32(1): 41-45. DOI: 10.1007/BF03345677 DOI: https://doi.org/10.1007/BF03345677
Fracassi F., Corradini S., Floriano D., Boari A., Aste G., Pietra M., Bergamini P.F. & Dondi F. 2015. Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane. Veterinary Record. 176(2): 49-49. DOI: 10.1136/vr.102546 DOI: https://doi.org/10.1136/vr.102546
Furuzono S., Meguro M., Miyauchi S., Inoue S., Homma T., Yamada K., Tagawa Y., Nara F. & Nagayama T. 2017. A novel aldosterone synthase inhibitor ameliorates mortality in pressure overload mice with heart failure. European Journal of Pharmacology. 795: 58-65. DOI: 10.1016/j.ejphar.2016.11.049 DOI: https://doi.org/10.1016/j.ejphar.2016.11.049
Goggs R., Chan D.L., Benigni L., Hirst C., Kellett-Gregory L. & Fuentes V.L. 2014. Comparison of computed tomography pulmonary angiography and point-of-care tests for pulmonary thromboembolism diagnosis in dogs. Journal of Small Animal Practice. 55(4): 190-197. DOI: 10.1111/jsap.12185 DOI: https://doi.org/10.1111/jsap.12185
Goy-Thollot I., Péchereau D., Kéroack S., Dezempte J.C. & Bonnet J.M. 2002. Investigation of the role of aldosterone in hypertension associated with spontaneous pituitary-dependent hyperadrenocorticism in dogs. Journal of Small Animal Practice. 43(11): 489-492. DOI: 10.1111/j.1748-5827.2002.tb00019.x DOI: https://doi.org/10.1111/j.1748-5827.2002.tb00019.x
Helm J.R., McLauchlan G., Boden L.A., Frowde P.E., Collings A.J., Tebb A.J., Elwood C.M., Herrtage M.E., Parkin T.D. & Ramsey I.K. 2011. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane. Journal of Veterinary Internal Medicine. 25(2): 251-260. DOI: 10.1111/j.1939-1676.2011.0696.x DOI: https://doi.org/10.1111/j.1939-1676.2011.0696.x
Hoffman J.M., Lourenço B.N., Promislow D.E.L. & Creevy K.E. 2018. Canine hyperadrenocorticism associations with signalment, selected comorbidities and mortality within North American veterinary teaching hospitals. Journal of Small Animal Practice. 59(11): 681-690. DOI: 10.1111/jsap.12904 DOI: https://doi.org/10.1111/jsap.12904
Hurley K.G. & Vaden S.L. 1998. Evaluation of urine protein content in dogs with pituitary-dependent hyperadrenocorticism. Journal of the American Veterinary Medical Association. 212(3): 369-373. DOI: https://doi.org/10.2460/javma.1998.212.03.369
Iuchi T., Akaike M., Mitsui T., Ohshima Y., Shintani Y., Azuma H. & Matsumoto T. 2003. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circulation Research. 92(1): 81-87. DOI: 10.1161/01.res.0000050588.35034.3c DOI: https://doi.org/10.1161/01.RES.0000050588.35034.3C
Kamenický P., Redheuil A., Roux C., Salenave S., Kachenoura N., Raissouni Z., Macron L., Guignat L., Jublanc C., Azarine A., Brailly S., Young J., Mousseaux E. & Chanson P. 2014. Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study. The Journal of Clinical Endocrinology and Metabolism. 99(11): E2144-2153. DOI: 10.1210/jc.2014-1783 DOI: https://doi.org/10.1210/jc.2014-1783
Keene B.W., Atkins C.E., Bonagura J.D., Fox P.R., Häggström J., Fuentes V.L., Oyama M.A., Rush J.E., Stepien R. & Uechi M. 2019. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine. 33(3): 1127-1140. DOI: 10.1111/jvim.15488 DOI: https://doi.org/10.1111/jvim.15488
Kim H., Han S., Song W., Kim B., Choi M., Yoon J. & Youn H. 2017. Retrospective study of degenerative mitral valve disease in small-breed dogs: survival and prognostic variables. Journal of Veterinary Science.18(3): 369-376. DOI: 10.4142/jvs.2017.18.3.369 DOI: https://doi.org/10.4142/jvs.2017.18.3.369
Marti C.N., Gheorghiade M., Kalogeropoulos A.P., Georgiopoulou V.V., Quyyumi A.A. & Butler J. 2012. Endothelial dysfunction, arterial stiffness, and heart failure. Journal of the American College of Cardiology. 60(16): 1455-1469. DOI: 10.1016/j.jacc.2011.11.082 DOI: https://doi.org/10.1016/j.jacc.2011.11.082
Martins F.S.M, Carvalho G.L.C., Jesus L., Pöppl A.G. & González F.H.D. 2019. Epidemiological, clinical, and laboratory aspects in a case series of canine hyperadrenocorticism: 115 cases (2010-2014). Pesquisa Veterinária Brasileira. 39(11): 900-908. DOI: 10.1590/1678-5150-PVB-6105 DOI: https://doi.org/10.1590/1678-5150-pvb-6105
Mattin M.J., Boswood A., Church D.B., López-Alvarez J., McGreevy P.D., O'Neill D.G., Thomson P.C. & Brodbelt D.C. 2015. Prevalence of and risk factors for degenerative mitral valve disease in dogs attending primary-care veterinary practices in England. Journal of Veterinary Internal Medicine. 29(3): 847-854. DOI: 10.1111/jvim.12591 DOI: https://doi.org/10.1111/jvim.12591
Nagata N., Kojima K. & Yuki M. 2017. Comparison of Survival Times for Dogs with Pituitary Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with Trilostane versus Untreated. Journal of Veterinary Internal Medicine. 31(1): 22-28. DOI: 10.1111/jvim.14617 DOI: https://doi.org/10.1111/jvim.14617
Novellas R., De Gopegui R.R. & Espada Y. 2008. Determination of renal vascular resistance in dogs with diabetes mellitus and hyperadrenocorticism. Veterinary Record. 163(20): 592-596. DOI: 10.1136/vr.163.20.592 DOI: https://doi.org/10.1136/vr.163.20.592
O’Neill D.G., Scudder C., Faire J.M., Church D.B., McGreevy P.D., Thomson P.C. & Brodbelt D.C. 2016. Epidemiology of hyperadrenocorticism among 210,824 dogs attending primary-care veterinary practices in the UK from 2009 to 2014. Journal of Small Animal Practice. 57(7): 365- 373. DOI: 10.1111/jsap.12523 DOI: https://doi.org/10.1111/jsap.12523
Ortega T.M., Feldman E.C., Nelson R.W., Willits N. & Cowgill L.D. 1996. Systemic arterial blood pressure and urine protein/creatinine ratio in dogs with hyperadrenocorticism. Journal of Veterinary and Medical Sciences. 209(10): 1724-1729 DOI: https://doi.org/10.2460/javma.1996.209.10.1724
Oui H., Jeon S., Lee G., Park S., Cho K.O. & Choi J. 2015. Tissue Doppler and strain imaging of left ventricle in Beagle dogs with iatrogenic hypercortisolism. Journal of Veterinary Science. 16(3): 357- 365. DOI: 10.4142/jvs.2015.16.3.357 DOI: https://doi.org/10.4142/jvs.2015.16.3.357
Ovaert P., Elliott J., Bernay F., Guillot E. & Bardon T. 2010. Aldosterone receptor antagonists - how cardiovascular actions may explain their beneficial effects in heart failure. Journal of Veterinary Pharmacology and Therapeutics. 33(2): 109-117. DOI: 10.1111/j.1365-2885.2009.01122.x DOI: https://doi.org/10.1111/j.1365-2885.2009.01122.x
Pöppl A.G., Coelho I.C., Silveira C.A., Moresco M.B. & Carvalho G.L. 2016. Frequency of endocrinopathies and characteristics of affected dogs and cats in southern Brazil. Acta Scientiae Veterinariae. 44(1): 1379. DOI: 10.22456/1679-9216.81099 DOI: https://doi.org/10.22456/1679-9216.81099
Prázný M., Jezková J., Horová E., Lazárová V., Hána V., Kvasnicka J., Pecen L., Marek J., Skrha J. & Krsek M. 2008. Impaired microvascular reactivity and endothelial function in patients with Cushing’s syndrome: influence of arterial hypertension. Physiological Research. 57(1): 13-22. DOI: 10.33549/physiolres.931126 DOI: https://doi.org/10.33549/physiolres.931126
Reid L.E., Behrend E.N., Martin L.G., Kemppainen R.J., Ward C.R., Lurye J.C., Donovan T.C. & Lee H.P. 2014. Effect of Trilostane and Mitotane on Aldosterone Secretory Reserve in Dogs with Pituitary‐Dependent Hyperadrenocorticism. Journal of Veterinary Internal Medicine. 28(2): 443-450. DOI: 10.1111/jvim.12276 DOI: https://doi.org/10.1111/jvim.12276
Smets P.M., Lefebvre H.P., Meij B.P., Croubels S., Meyer E., Van de Maele I. & Daminet S. 2012. Long-term follow-up of renal function in dogs after treatment for ACTH-dependent hyperadrenocorticism. Journal of Veterinary Internal Medicine. 26(3): 565-574. DOI: 10.1111/j.1939-1676.2012.00915.x DOI: https://doi.org/10.1111/j.1939-1676.2012.00915.x
Soares F.A.C., Matheus J.P., Carvalho G.L., Neuwald E.B., Pöppl A.G., Valle S.F. & González F.H.D. 2016. Cardiocirculatory, biochemical and hemostatic evaluation of dogs with hyperadrenocorticism at diagnosis and after treatment. Korean Journal of Veterinary Research. 56(3): 161-166. DOI: 10.14405/kjvr.2016.56.3.161 DOI: https://doi.org/10.14405/kjvr.2016.56.3.161
Soares F.A.C., Neuwald E.B., Mombach V.S., D'Avila A.E.R., Conrado F.O. & González F.H.D. 2012. Systolic blood pressure of dogs at hospital and domestic environment. Ciência Rural. 42(7): 1243-1248. DOI: 10.1590/S0103-84782012005000036 DOI: https://doi.org/10.1590/S0103-84782012005000036
Summerfield N. 2018. Simplifying mitral valve disease diagnostics. In Practice. 40: 7-11. DOI: 10.1136/inp.k912 DOI: https://doi.org/10.1136/inp.k912
Takano H., Kokubu A., Sugimoto K., Sunahara H., Aoki T. & Fijii Y. 2015. Left Ventricular structural and functional abnormalities in dogs with hyperadrenocorticism. Journal of Veterinary Cardiology. 17(3): 173-181. DOI: 10.1016/j.jvc.2015.07.002 DOI: https://doi.org/10.1016/j.jvc.2015.07.002
Tilley L.P. 1992. Essentials of Canine and Feline Electrocardiography. 3rd edn. Philadelphia: Lea & Febiger, pp.21-39.
Vila B.C., Vanhoni M.S. & Sousa M.G. 2023. QT interval instability and¬ variability in¬ dogs with ¬naturally-occurring hypercortisolism. Veterinary Research Communications. 47(1): 121-130. DOI: 10.1007/s11259-022-09936-1 DOI: https://doi.org/10.1007/s11259-022-09936-1
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Frederico Aécio Carvalho Soares, Daniela Jardim Lopes, Caroline de Moraes Pertile, Mirela Caberlon, Álan Gomes Pöppl, Félix Hilário Diaz González
This work is licensed under a Creative Commons Attribution 4.0 International License.
This journal provides open access to all of its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. Such access is associated with increased readership and increased citation of an author's work. For more information on this approach, see the Public Knowledge Project and Directory of Open Access Journals.
We define open access journals as journals that use a funding model that does not charge readers or their institutions for access. From the BOAI definition of "open access" we take the right of users to "read, download, copy, distribute, print, search, or link to the full texts of these articles" as mandatory for a journal to be included in the directory.
La Red y Portal Iberoamericano de Revistas Científicas de Veterinaria de Libre Acceso reúne a las principales publicaciones científicas editadas en España, Portugal, Latino América y otros países del ámbito latino
